Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.
Qyuns Therapeutics Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, develops and commercialises therapeutic products and serves investors in the Hong Kong capital market through its H-share listing. The company’s board has initiated on-market share repurchases under an existing mandate, buying back 1,575,800 shares for about HK$31.16 million, representing roughly 0.69% of its issued share capital, citing a belief that the current share price significantly undervalues the company and aiming to bolster market confidence and enhance investment value, while cautioning that any further buybacks will depend on market conditions and remain at the board’s discretion.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a China-incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercialising therapeutic products, with its shares traded on The Stock Exchange of Hong Kong under stock code 2509.
Average Trading Volume: 519,258
Technical Sentiment Signal: Hold
Current Market Cap: HK$4.65B
Learn more about 2509 stock on TipRanks’ Stock Analysis page.